 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H22N2O2 |
| Molar mass | 358.441 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SDB-005 (also known asNA-PINAC using systematicEUDA nomenclature)[1] is anindazole-basedsynthetic cannabinoid that has been sold online as adesigner drug.[2] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole coreanalog ofPB-22 where the8-hydroxyquinoline has also been replaced with anaphthalene group.
The code number SDB-005 was originally used for a different compound, theN-phenyl instead ofN-benzyl analogue ofSDB-006. This compound is a potentagonist of theCB1 receptor (Ki = 21 nM) andCB2 receptor (Ki = 140 nM).[3]
However, SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as adesigner drug, and was entered into theEMCDDA synthetic drug database under this name.[4] Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.
